Skip to content

Colchicine in Obese-inflammatory Heart Failure with Preserved Ejection Fraction: a Randomized, Controlled, Open-Label Trial

Colchicine in Obese-inflammatory Heart Failure with Preserved Ejection Fraction: a Randomized, Controlled, Open-Label Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100043340
Enrollment
Unknown
Registered
2021-02-11
Start date
2020-10-01
Completion date
Unknown
Last updated
2021-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure with preserved ejection fraction, Obesity

Interventions

Treatment Group
:Colchicine 0.5mg Qd p.o in addition to optimized treatment for heart failure
Placobo:placebo in addition to optimized treatment for heart failure

Sponsors

Second Xiangya Hospital, Central South University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Symptoms and signs of heart failure (NYHA II-IV); (2) Recent imaging study ( 50%; (3) HFA-PEFF score >= 5 (How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC); (4) hsCRP > 2.0mg/L; (5) BMI >= 24kg/m2.

Exclusion criteria

Exclusion criteria: (1) Aged 3ULT). (12) Absolute neutrophil count < 1,500/mm3 (13) Absolute platelet count < 100 x 10^12/L. (14) Allergy to colchicine. (15) Pregnancy or breastfeeding. (16) Inability to give informed consent.

Design outcomes

Primary

MeasureTime frame
peak oxygen consumption;

Secondary

MeasureTime frame
6-min walking distance;left atrial volume index;left ventricular mass index;e';E/e';TR velosity;LVEF;The Kansas city cardiomyopathy questionnaire;biomarkers of heart failure;biomarkers of fibrosis;biomarkers of inflammation;co-outcome of re-hospitalization for HF, present to emerency department for HF, cardiovascular death;

Countries

China

Contacts

Public ContactDaoquan Peng

Department of Cardiovascular Medicine, Second Xiangya Hospital of Central South University

pengdq@csu.edu.cn+86 13974822567

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026